• Explore /
  • Poster
  • / First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.

First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.

Abstract Poster

Authors

David S. Hong

David S. Hong

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

David S. Hong , Ignacio Garrido-Laguna , Ian E. Krop , Vivek Subbiah , Theresa Louise Werner , Christine M Cotter , Erika Paige Hamilton , Karen Velastegui , Dawei Xuan , Roberto Bugarini , Ashwin Gollerkeri , Howard A. Burris III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT02078752

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2520)

DOI

10.1200/jco.2015.33.15_suppl.2520

Abstract #

2520

Poster Bd #

236

Abstract Disclosures

Similar Posters

First Author: Soohyeon Lee

First Author: Sara A. Hurvitz

First Author: Johanna C. Bendell

Poster

2019 Gastrointestinal Cancers Symposium

Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.

Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.

First Author: Taroh Satoh